Insurance Assistance

Your dedicated Case Manager has insurance experience — specifically trained to understand how to work with insurance companies — who will be your personal advocate to help you navigate through the insurance process.

Benefits investigation with Patient Authorization Form

Before Humatrope DirectConnect can contact you and begin working with your case, we must have your consent. We can do this a few ways. You can provide your permission via the electronic Patient Authorization Form below or by downloading a copy of the Patient Authorization Form and returning it via fax ((800) 642-5442), email (patientauth@lashgroup.com), or mail to: Patient Authorization Form, PO Box 220301, Charlotte, NC 28222.

Download Patient Authorization Form - English

Download Patient Authorization Form - Spanish

Appeals support*

After we receive your permission, we can contact the insurance company on your behalf to request insurance coverage, which is called a prior authorization. Sometimes this is approved and sometimes it is denied. For prior authorization denials, eligible patients may also get support throughout the appeals process from Humatrope DirectConnect. Our Appeals Specialists are medical professionals with insurance experience who are able to help you:

  • Understand the appeals process and how to work through it
  • Write 1st- and 2nd- level appeal letters for eligible patients, review them with your doctor for approval, and submit them to insurance companies
  • Your dedicated Case Manager will continue to serve as your main point of contact, and will follow up and provide updates to keep patients, caregivers, and doctors aware of the appeal case status.

*For internal appeals only. For on-label indications for commercially insured patients only. Appeals support is not available for patients who are residents of Massachusetts, Michigan, Minnesota, or Rhode Island or for patients who receive treatment from a physician who practices in those states. This program is also not available for patients whose prescription is paid in part or full by any government funded program, including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, the VA, TRICARE/CHAMPUS, DOD, or any State Patient or Pharmaceutical Assistance Program. Offer void where prohibited by law. Available only in the United States (US) and Puerto Rico (PR) for residents of the US and PR. This is not a guarantee of insurance or financial assistance. All benefits are subject to the insured's plan. Under no circumstances shall Humatrope DirectConnect or Eli Lilly and Company be held directly or indirectly responsible or liable for payment of any claims, benefits, or costs.

Humatrope FastTrack

Children who need growth hormone treatment need to start while they still have time to grow. Humatrope FastTrack is a program that helps eligible patients* start Humatrope as soon as possible. If you qualify and your doctor agrees, Humatrope FastTrack can help you receive Humatrope at no charge throughout the claims process while you’re waiting for approval.

*Patients must meet eligibility criteria for initial and subsequent requests. There is a possbility that coverage may ultimately be denied. Restrictions apply for patients who are residents of Minnesota and Rhode Island, or for patients who receive a treatment from a physician who practices in those states. This program is also not available for patients whose prescription is paid in part or full by any government funded program, including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, the VA, CHAMPUS, DOD, TriCare, or any State Patient or Pharmaceutical Assistance Program. Absent a change in Massachusetts law, effective June 30, 2019, Massachusetts residents will no longer be able to participate in this program. Offer void where prohibited by law. Available only in the United States (US) and Puerto Rico (PR) for residents of the US and PR.

Ongoing support

We'll stay in touch to offer help throughout your treatment experience, with updates on your insurance coverage status, follow-up while you start treatment, and assistance when it’s time to reauthorize your Humatrope prescription coverage.

Coping with therapy

Talking With Your Child About Therapy

You know your child better than anyone else, and talking often helps keep it that way. Throughout treatment, here are some tips to keep the conversation going.

Talk About Expectations. Keep your child involved from the start, and make sure you both know what to expect by talking with your healthcare professional. Kids who know what to expect from the start may have more of a reason to stick with their therapy.

Learn More Together. As you learn about growth and treatment, share what you discover with your child. This can help guide kids to the right kind of information, and help them feel more in control of their growth.

Keep Track of Questions. Answer questions as best you can, and write down questions you can't answer. Let your child ask the questions at the next doctor's visit — children may feel more in control if they understand what's going on.

Connect With Friends. Support groups throughout the country have programs focused on kids on a similar growth treatment journey, and they often meet once a year—giving you both a chance to learn more, connect with other families, and make new friends who can understand what you're going through.

Indications and Important Safety Information
Indications

Humatrope® (somatropin for injection) is used to treat:

  • Children who do not make enough growth hormone on their own, have short stature associated with Turner syndrome, or have SHOX deficiency; have idiopathic short stature, which means they are shorter than 98.8% of other children of the same age and sex, are growing at a rate not likely to allow them to reach normal adult height, and for whom no other cause of short stature can be found; were born smaller than normal for the number of weeks of pregnancy and who do not catch up in height by 2 to 4 years of age.
  • Adults who have growth hormone deficiency that began either in adulthood (as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma) or in childhood. Patients treated for growth hormone deficiency in childhood whose bones have stopped growing should be reevaluated to determine if they should continue growth hormone.

IMPORTANT SAFETY INFORMATION FOR HUMATROPE

What is the most important information I should know about Humatrope?

  • Do not take Humatrope if you are having serious complications after having open heart surgery, abdominal surgery, or serious injuries involving many body systems, or are having life-threatening breathing problems. Deaths have been reported in such cases.
  • Do not use Humatrope in children with Prader-Willi syndrome who are severely obese or have a history of blocked upper airways or other severe breathing problems, or sleep apnea. Deaths have been reported in such cases. Humatrope is not approved for the treatment of patients with Prader-Willi syndrome.
  • Do not use Humatrope if you have active cancer. Growth hormone deficiency can be an early sign of some tumors in the brain or pituitary gland. The presence of these types of tumors should be ruled out by your doctor before you start Humatrope.
  • Serious allergic reactions have been reported with Humatrope. Humatrope is contraindicated if you know you have allergies to growth hormone or any of its ingredients. Tell your doctor if you have an allergic reaction. Do not mix Humatrope with the supplied diluent if you are allergic to metacresol or glycerin.
  • Your doctor should check your blood sugar regularly while you are taking Humatrope, especially if you have diabetes, pre-diabetes, or risk factors for diabetes. New cases of type 2 diabetes have been reported in patients taking Humatrope.
  • Tell your doctor if you have any visual changes accompanied by headache, nausea, and/or vomiting while taking Humatrope. This may be a sign of increased pressure in the brain.
  • Adults may retain water during Humatrope treatment. This may be brief and may increase with higher doses of Humatrope.
  • If you have hypoadrenalism and are on glucocorticoid replacement therapy, your doctor may increase your dosage when you initiate growth hormone treatment.
  • Your doctor should test your thyroid function periodically during Humatrope therapy. Thyroid hormone treatment may need to be started or adjusted.
  • Fracture in the ball of the hip joint can occur in children who have endocrine problems and in children who have rapid growth. Any child taking Humatrope who develops a limp or complains of hip or knee pain should be seen by a doctor to check for this.
  • Progression of curvature of the spine (scoliosis) can occur in children who have rapid growth. Humatrope has not been shown to increase the occurrence of this condition. If the child has scoliosis, the doctor should carefully monitor the progression of the scoliosis during Humatrope treatment.
  • Cases of pancreatitis (inflammation of the pancreas) have been reported rarely in children and adults receiving growth hormone. Consult a doctor if you develop abdominal pain while taking Humatrope.
  • You should rotate your injection sites to avoid breakdown of skin and fat. Seek prompt medical attention for any allergic reaction you experience to the injection of Humatrope.

WHO SHOULD NOT TAKE HUMATROPE

Who should not take Humatrope?

Humatrope should not be used by:

  • People with serious complications after having open heart surgery, abdominal surgery, serious injuries involving many body systems, or with life-threatening breathing problems
  • Children with Prader-Willi syndrome who are severely obese or have a history of severe breathing problems
  • People with active cancer
  • People who have had an allergic reaction to growth hormone
  • People with diabetic disease of the retina (the lining in the back of the eyeball)
  • Children who have closed growth plates in their bones
TALK TO YOUR DOCTOR

What should I tell my doctor before taking Humatrope?

Tell your doctor about all of your prescription and over the counter drugs, including cyclosporine, hormone replacement therapy, insulin or other diabetes medications, drugs containing steroids, or drugs for seizures. These medications may need to be adjusted while taking Humatrope.

COMMON SIDE EFFECTS

What are the possible side effects of Humatrope?

Common side effects reported in adults and children taking Humatrope include injection site reactions, allergic reactions to the diluent, and hypothyroidism. Additional common side effects in adults include swelling, joint pain, muscle pain, carpal tunnel syndrome, unusual skin sensations, and high blood sugar. You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

STORING HUMATROPE

How should I store Humatrope?

Humatrope must be kept refrigerated (36° to 46°F [2° to 8°C]) before and after it is mixed. Do not freeze. Once Humatrope has been mixed and is in liquid form, cartridges must be used within 28 days and vials must be used within 14 days. Throw away any unused Humatrope in a cartridge after 28 days and in a vial after 14 days. Before giving an injection, check the manufacturer’s expiration date on the cartridge or vial. Do not use the cartridge or vial if it has expired.

ADDITIONAL INFORMATION

Humatrope is available by prescription only.

Click to access Patient Information-Cartridge, Patient Information-Vial, and Full Prescribing Information.

See Full Pen User Manual that accompanies the HumatroPen® 6 mg, 12 mg, and 24 mg.

Humatrope is a registered trademark owned or licensed by Eli Lilly & Company, its subsidiaries, or affiliates.
HG CON ISI 14OCT2016